Evidence map›Paper›PMID 30654078›Full record

ArticleJournal of the American Academy of Dermatology2019

Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials.

Marilyn T Wan, Drew A Torigian, Abass Alavi, Judith Alvarez, Zelma C Chiesa Fuxench, Megan H Noe, Maryte Papadopoulos, Daniel B Shin, Junko Takeshita, Thomas J Werner and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Academy of Dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Definitions of Incidental [Diagnostics (Basel, Switzerland) · 2024
    Review
  4. Returning Incidental Research Findings FromArthritis care & research · 2024
    Article
  5. The Diagnostic Yield of [Diagnostics (Basel, Switzerland) · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marilyn T WanDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Drew A TorigianDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Abass AlaviDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Judith AlvarezDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Zelma C Chiesa FuxenchDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Megan H NoeDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Maryte PapadopoulosDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Daniel B ShinDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Junko TakeshitaDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Thomas J WernerDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Nehal N MehtaCardiopulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Joel M GelfandDepartment of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: Joel.Gelfand@uphs.upenn.edu.
University of Pennsylvania · USHospital of the University of Pennsylvania · USNational Heart Lung and Blood Institute · US

Funding

Study Design and Data AnalysisP30AR069589 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice · 2016 to 2026
$8.6M
A trial to determine the effect of psoriasis treatment on cardiometabolic diseaseR01HL111293 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GELFAND, JOEL M · 2012 to 2017
$3.8M
NHLBI NIH HHS R01 HL111293NIAMS NIH HHS P30 AR069589
6 · The paper itself

Abstract

backgroundThere has been an increase in the number of psoriasis treatments being investigated in clinical trials. Patients may have undiagnosed issues at the start of a study which may become identified during follow-up as incident medicinal conditions. The prevalence of incidental findings in patients with moderate-to-severe psoriasis presenting for clinical trials is unknown.

objectiveDetermine the prevalence of incidentalomas and rate of malignancy identified by fludeoxyglucose F 18 (FDG) positron emission tomography/computed tomography (PET/CT) imaging in clinical trial patients with moderate-to-severe psoriasis.

methodsA cross-sectional secondary analysis of patients with moderate-to-severe psoriasis who underwent FDG PET/CT scans at the baseline visit, before randomization, for 3 phase 4 clinical trials on vascular inflammation in psoriasis. Only patients without active infection, malignancy, or uncontrolled comorbidities were eligible for the clinical trials.

resultsA total of 259 healthy patients with moderate-to-severe psoriasis underwent an FDG PET/CT scan as part of the study procedures. In all, 31 patients (11.97%) (95% confidence interval [CI], 8.28-16.56) had clinically significant incidentalomas on the baseline FDG PET/CT scan. Univariate logistic regression demonstrated that with every increase of 10 years of age, there was an approximate 30% increased risk of discovery of an incidentaloma (odds ratio, 1.30; 95% CI, 1.01-1.68). Of those patients with findings suggestive of malignancy (n = 28), 6 were confirmed to have cancer, resulting in a 2.31% (95% CI, 0.9-5.0) prevalence of malignancy. The positive predictive value of a true cancer was 31.58% (range, 21%-54%). LIMITATIONS: Generalizability and lost to follow-up.

conclusionIncidentalomas on FDG PET/CT imaging are common in otherwise healthy, asymptomatic patients with moderate-to-severe psoriasis in clinical trials. Our results can help inform interpretation of clinical trial safety data and emphasize the importance of compliance with cancer screening recommendations.

Indexed as

Incidental FindingsPositron Emission Tomography Computed TomographyWhole Body ImagingAdultAgedAsymptomatic DiseasesClinical Trials as TopicComorbidityCross-Sectional StudiesEthnicityFemaleFluorine RadioisotopesFluorodeoxyglucose F18HumansMaleMiddle AgedFluorine-18Fluorine RadioisotopesFluorodeoxyglucose F18RadiopharmaceuticalsbiologicsFDG PET/CTincidental findingspsoriasisrandomized controlled trials

Identifiers

PMID30654078
PMCPMC6536299
OpenAlexW2910994451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.